IFNG and cancer: Although TFR1-positive cancer cells can be killed by H-ferritin drug nanocarrier when treated with IFN-γ, TFR1-deficient cells can upregulate the expression of PD-L1, CXCL9, and CXCL10 to promote immune escape.